Sylvie Boyer

Sylvie Boyer i

INSERM - Paris / France
Economics & Econometrics / Economics
AD Scientific Index ID: 4420404
person_outline Sylvie Boyer's MOST POPULAR ARTICLES
1-) Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1NAMSAL ANRS 12313 Study GroupNew England Journal of Medicine 381 (9), 816-826, 20192392019
2-) Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trialCC Iwuji, J Orne-Gliemann, J Larmarange, E Balestre, R Thiebaut, ...The lancet HIV 5 (3), e116-e125, 20182372018
3-) The point-of-care laboratory in clinical microbiologyM Drancourt, A Michel-Lepage, S Boyer, D RaoultClinical microbiology reviews 29 (3), 429-447, 20161522016
4-) Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open …A Calmy, TT Sanchez, C Kouanfack, M Mpoudi-Etame, S Leroy, ...The lancet HIV 7 (10), e677-e687, 20201372020
5-) Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factorsS Boyer, I Clerc, CR Bonono, F Marcellin, PC Bilé, B VentelouSocial science & medicine 72 (8), 1383-1392, 20111362011